Start Time: 16:30 January 1, 0000 5:01 PM ET

Vaxart, Inc. (NASDAQ:VXRT)

Q2 2023 Earnings Conference Call

August 03, 2023, 16:30 PM ET

Company Participants

Andrei Floroiu - President and CEO

James Cummings - Chief Medical Officer

Sean Tucker - SVP and Chief Scientific Officer

Phil Lee - CFO

Brant Biehn - SVP and Business Operations

Conference Call Participants

Charles Duncan - Cantor Fitzgerald

Mayank Mamtani - B. Riley Securities

Operator

Greetings, and welcome to the Vaxart Business Update and Second Quarter 2023 Financial Results Conference Call. A question-and-answer session will follow management's opening remarks. Individual investors may submit written questions to ir@vaxart.com. As a reminder, this conference is being recorded.

I would now like to turn the webcast over to your host, Brant Biehn, Senior Vice President and Business Operations. Thank you. You may begin.

Brant Biehn

Good afternoon, and welcome to today's call. Joining us from Vaxart are Andrei Floroiu, our Chief Executive Officer; Dr. Sean Tucker, our Founder and Chief Scientific Officer; Dr. James Cummings, our Chief Medical Officer; and Phil Lee, or Chief Financial Officer.

Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress, including statements about its ongoing or planned clinical trials.

Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, and other risks described in the Risk Factors section of Vaxart's most recently filed Annual Report on Form 10-K and also on other periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements after the date of this call.

I'll now turn the call over to Andrei Floroiu. Andrei?

Andrei Floroiu

Thank you, Brant, and thank you to all of you for joining us today. On today's call, we will highlight the recent progress we have made on our norovirus oral pill vaccine program. We'll also look ahead for remaining planned milestones for the second half of the year, and briefly discuss our COVID program before opening the call to your questions.

During the second quarter, we are pleased to report positive preliminary top line results from our Phase 2 dose ranging study for our bivalent norovirus oral vaccine candidate within our stated timeline. James will provide a review of that data and what it means for this potentially groundbreaking vaccine. It is important to point out that this data builds on the growing body of evidence that validates Vaxart’s platform as we explore the potential advantages of mucosal vaccination.